Lataa...
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2020-03-01
|
| Sarja: | International Journal of Molecular Sciences |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/1422-0067/21/7/2275 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|